Do-It-Yourself RNAi Tech
Worcester's RXi Pharmaceuticals Corp. has acquired an exclusive license to technology that could allow patients to administer RNAi treatments themselves.
RXi acquired the license through the exercise of an option it had for the technology with Advirna LLC. The technologies under the license cover four distinct approaches to the self delivery of RNAi therapeutics.
The advantages of the Advirna system include the ability to administer RNAi treatments without the added expense of other biological agents or delivery vehicles, the ability for patients to administer RNAi treatments without professional supervision, the ability to target certain tissues and reduced side effects from the treatments.
RXi said the technology would be part of its plan to develop RNAi treatments for inflammatory diseases such as rheumatoid arthritis, diabetes and Crohn's disease.
RXi was co-founded by UMass Medical School professor and Nobel Prize winner Craig Mello. RNAi seeks to treat diseases by interfering with the genes suspected of causing those diseases.
WBJ Web Partners
Most Recent
Most Recent
0 Comments